- Home
- /
- CJC-1295 with DAC 5mg
CJC-1295 with DAC 5mg
Certificate of Analysis
HPLC + Mass Spectrometry included with order
CJC-1295 with Drug Affinity Complex (DAC) is an extended-release variant of Modified GRF (1-29). The DAC modification allows the peptide to bind to albumin in the bloodstream, dramatically extending its half-life from minutes to approximately 6-8 days in preclinical models.
This sustained-release profile makes CJC-1295 DAC suitable for research protocols examining prolonged growth hormone elevation without frequent administration. Studies have investigated its effects on growth hormone pulsatility, IGF-1 levels, and body composition parameters.
The DAC variant produces a more sustained, less pulsatile GH release pattern compared to the no-DAC version, making each variant suited to different research objectives.
Independently Verified Purity: 99.429%
Tested by Janoshik Analytical (Prague) — Task #73099, 1 August 2025.
Actual content: 5.03mg per vial (0.6% overfilled vs stated 5mg dose).
Verification: janoshik.com/verify — Key:
Y6F5K8B7JUVXNote: This is a 5mg per vial product.
Specifications
| Also Known As | CJC-1295 DAC, DAC:GRF |
| Molecular Weight | 3647.28 g/mol |
| CAS | 863288-34-0 |
| Half-life | ~6-8 days (preclinical) |
| Appearance | White lyophilised powder |
| Storage | 2-8°C, protect from light |
This product is sold strictly for in-vitro research and laboratory purposes. Not for human or animal consumption. Not evaluated by the MHRA or FDA. Must be 18+ to purchase. By purchasing, you agree to our Research Disclaimer and Terms of Service.
| Compound Name | CJC-1295 with DAC 5mg |